More About Us
More About Lobe Sciences
In July of 2024, Lobe Sciences underwent a series of changes in ownership, board, and advisory team.
Short biographies and a brief overview for our company leadership can be found above in both the Our Team tab and on the Corporate Profile page.
Altemia, Inc. is focused on the commercialization of treatments to address diseases associated with membranopathy.
Membranopathy is a fatty acid disorder caused by an error in metabolism.
Our initial target is a deficiency associated with Sickle Cell Disease (SCD), the rare orphan disease primarily impacting children and young adults.
Altemia® Medical Food
A second opportunity came about thru a late stage development product for the treatment of a rare genetic disorder called Sickle Cell Disease (SCD).
Cynaptec is a biopharmaceutical company dedicated to developing innovative therapies for neurological and psychiatric disorders Cynaptec’s initial development program is focused on the use of its proprietary Conjugated Psilocin™ compound for treatment of the significant unmet medical needs of patients with Chronic Cluster Headache, with an additional preliminary proof-of-concept to assess potential utility for substance use disorders.
Conjugated Psilocin™ is a novel, patented, oral, stable analog of psilocin, the active metabolite of the prodrug psilocybin, designed to enhance bioavailability and therapeutic efficacy, which has been identified as having therapeutic potential in a variety of neurological conditions.
About Cynaptec Pharmaceuticals
